Evidence map›Paper›PMID 19014437›Full record

ArticleBMC molecular biology2008

Construction of non-polar mutants in Haemophilus influenzae using FLP recombinase technology.

Erin Tracy, Fang Ye, Beth D Baker, Robert S Munson

Open access · hybridAbstract read
In one paragraph

Article in BMC molecular biology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 49 citations in OpenAlex.

  1. Frontiers in cellular and infection microbiology · 2026
    Article
  2. Article
  3. Antimicrobial agents and chemotherapy · 2020
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Inactivation of the Thymidylate SynthaseFrontiers in cellular and infection microbiology · 2017
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Erin TracyCenter for Microbial Pathogenesis in The Research Institute at Nationwide Children's Hospital, Columbus, OH, USA. Erin.Tracy@nationwidechildrens.org
Fang Ye
Beth D Baker
Robert S Munson
Nationwide Children's Hospital · USInterface (United States) · US

Funding

DETERMINANTS OF H. INFLUENZAE VIRULENCE IN OTITIS MEDIAR01DC003915 · NIDCD · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI GOODMAN, STEVEN D · 1999 to 2025
$12.5M
NTHi Type IV pili: expression and vaccine potentialR01DC007464 · NIDCD · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI MUNSON, ROBERT S. · 2006 to 2010
$2.2M
VIRAL RESPIRATORY PATHOGENS RESEARCH UNIT /VRPRU/-266030040-266030040N01AI030040 · NIAID · UNIVERSITY OF IOWA · PI APICELLA, MICHAEL A. · 2003 to 2006
–
NIAID NIH HHS N01 AI030040NIDCD NIH HHS R01 DC003915NIDCD NIH HHS R01DC003915NIDCD NIH HHS R01 DC007464NIDCD NIH HHS R01DC007464
6 · The paper itself

Abstract

backgroundNontypeable Haemophilus influenzae (NTHi) is a gram-negative bacterium that causes otitis media in children as well as other infections of the upper and lower respiratory tract in children and adults. We are employing genetic strategies to identify and characterize virulence determinants in NTHi. NTHi is naturally competent for transformation and thus construction of most mutants by common methodologies is relatively straightforward. However, new methodology was required in order to construct unmarked non-polar mutations in poorly expressed genes whose products are required for transformation. We have adapted the lambda red/FLP-recombinase-mediated strategy used in E. coli for use in NTHi.

resultsA cassette containing a spectinomycin resistance gene and an rpsL gene flanked by FRT sites was constructed. A PCR amplicon containing 50 base pairs of DNA homologous to the 5' and 3' ends of the gene to be disrupted and the cassette was generated, then recombineered into the target NTHi gene, cloned on a plasmid, using the lambda recombination proteins expressed in E. coli DY380. Thus, the gene of interest was replaced by the cassette. The construct was then transformed into a streptomycin resistant NTHi strain and mutants were selected on spectinomycin-containing growth media. A plasmid derived from pLS88 with a temperature sensitive replicon expressing the FLP recombinase gene under the control of the tet operator/repressor was constructed. This plasmid was electroporated into the NTHi mutant at the permissive temperature and FLP expression was induced using anhydrotetracycline. The recombinase recognizes the FRT sites and eliminates the antibiotic cassette by site-specific recombination, creating the unmarked non-polar mutation. The plasmid is cured by growth of cells at the restrictive temperature.

conclusionThe products of the genes in the NTHi pilABCD operon are required for type IV pilus biogenesis and have a role in transformation. We demonstrated the utility of our methodology by the construction of a non-polar pilA mutation in NTHi strain 2019 and complementation of the mutation with a plasmid containing the pilA gene. Utilization of this approach allowed us to readily generate unmarked non-polar mutations in NTHi genes.

Indexed as

MutagenesisMutationBacteriophage lambdaDNA NucleotidyltransferasesEscherichia coli ProteinsFimbriae ProteinsGenetic EngineeringHaemophilus influenzaeOperonRecombination, GeneticRibosomal Protein S9Transformation, BacterialViral ProteinsDNA NucleotidyltransferasesEscherichia coli ProteinsFimbriae ProteinsFLP recombinaseRibosomal Protein S9RpsI protein, E coliViral Proteins

Identifiers

PMID19014437
PMCPMC2625361
OpenAlexW2104170174

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.